{
    "Trade/Device Name(s)": [
        "Aptiva APS IgG Reagent",
        "Aptiva APS IgM Reagent"
    ],
    "Submitter Information": "Inova Diagnostics, Inc.",
    "510(k) Number": "K223093",
    "Predicate Device Reference 510(k) Number(s)": [
        "K092181",
        "K970551",
        "K091556"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MID",
        "MSV"
    ],
    "Summary Letter Date": "December 14, 2023",
    "Summary Letter Received Date": "December 15, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5660"
    ],
    "Regulation Name(s)": [
        "Multiple Autoantibodies Immunological Test System"
    ],
    "Analyte Class(es)": [
        "autoimmune",
        "immunology"
    ],
    "Analyte(s)": [
        "anti-cardiolipin (aCL) IgG",
        "anti-beta 2 glycoprotein 1 (a\u03b22GPI) IgG",
        "anti-cardiolipin (aCL) IgM",
        "anti-beta 2 glycoprotein 1 (a\u03b22GPI) IgM"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Aptiva System",
        "Aptiva Multi-Analyte System"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescent immunoassay",
        "Particle-based multi-analyte technology (PMAT)"
    ],
    "Methodologies": [
        "Solid phase immunoassay",
        "Microparticle-based detection"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Kit",
        "Assay",
        "Component"
    ],
    "Document Summary": "FDA 510(k) summary for Aptiva APS IgG and IgM Reagents using particle-based fluorescent immunoassay on the Aptiva System for semi-quantitative detection of anti-cardiolipin and anti-beta 2 glycoprotein 1 antibodies.",
    "Indications for Use Summary": "Semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (a\u03b22GPI) IgG or IgM autoantibodies in human serum as an aid in the diagnosis of primary and secondary antiphospholipid syndrome (APS), when used in conjunction with other laboratory and clinical findings, intended for use with the Aptiva System.",
    "fda_folder": "Immunology"
}